SAB Biotherapeutics, Inc. (SABSW) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

10.3x

Market Cap

$251587.80

MomentumView details →

1D Return

+0.43%

YTD Return

−24.68%

RSI (14)

51.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

10.3x

Market Cap

$251587.80

RSI (14)

51.0

MomentumView details →

1D Return

+0.43%

YTD Return

−24.68%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−5.95%

ROA (TTM)

−5.36%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+189.25%

FCF YoY

—

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

+105.98%

EBITDA YoY

+71.69%

EarningsView details →

EPS (Actual)

−$0.28

EPS Surprise

1.06%

Beats (12Q)

2/12

Next Q EPS Est

−$0.27

Avg Surprise (4Q)

31.76%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

9.22x

Quick Ratio

9.22x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−12.78M

Op. CF (TTM)

−68.21M

Next earningsNov 17, 2026 →

Latest newsMore news →

No recent news for SABSW.

Similar companies

NRx Pharmaceuticals, Inc.NRXPW Ainos, Inc.AIMDW BriaCell Therapeutics Corp. WarrantBCTXZ Lyra Therapeutics, Inc.LYRA CDT Equity Inc.CDTTW Altamira Therapeutics Ltd.CYTO Find similar companies →

Latest newsMore news →

No recent news for SABSW.